Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Hill, Andrew; Sahib Abdulamir, Ahmed; Ahmed, Sabeena; Asghar, Asma; E Babalola, O; Basri, Rabia; Chaccour, Carlos; Zeeshan Khan Chachar, Aijaz; Tauib Mohammed Chowdhury, Abu; G. Elgazzar, Ahmed; Ellis, Leah; Falconer, Jonathan; Garratt, Anna; Hany, Basma; A. Hashim, Hashim; Ul Haque, Wasim; Hayat, Arshad; He, Shuixiang; Jamshidian, Ramin; Ali Khan, Wasif; Kirti, Ravi; Krolewiecki, Alejandro; Lanusse, Carlos; Levi, Jacob; Mahmud, Reaz; Ahmed Mangat, Sermand; McCann, Kaitlyn; Mohan, Anant; Shakshi Niaee, Mortezza; Okumuş, Nurullah; Pilkington, Victoria; Saha Podder, Chinmay; Qavi, Ambar; Raad, Houssam; Sadegh Rezai, Mohammaed; Sasank, Surapaneni; Spoorthi, Veerapaneni; Menon Suri, Tejas; Wang, Junzheng; Wentzel, Hannah

doi:10.21203/rs.3.rs-148845/v1

Public

Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Shared by NobleBlocks on Jan 19, 2021 • 12:00 AM UTC

Authors:

Andrew Hill

Ahmed Sahib Abdulamir

Sabeena Ahmed

Abstract

<title>Abstract</title> Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin i...

Subject

Ivermectin

Medicine

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!